Theravance Biopharma
TBPH
93 hedge funds and large institutions have $1.55B invested in Theravance Biopharma in 2018 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 10 closing their positions.
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
71% more call options, than puts
Call options by funds: $1.69M | Put options by funds: $983K
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
43% more capital invested
Capital invested by funds: $1.08B → $1.55B (+$464M)
8% more funds holding
Funds holding: 86 → 93 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.16% less ownership
Funds ownership: 87.19% → 86.03% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$19.9M |
| 2 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$13.1M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.94M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.44M |
| 5 |
Millennium Management
New York
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$26.8M |
| 2 |
First Manhattan
New York
|
-$16.9M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.45M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
-$5.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.94M |
TBPH Hedge Fund Activity: Q3 2018 in Review
93 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2018, worth a combined $1.55B — up 43% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TBPH positions and 10 closed out — a net gain of 9 holders — while 31 added to existing stakes and 21 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $19.9M. The largest seller was Armistice Capital, exiting entirely with an estimated $26.8M sold.
- 93 institutional investors held Theravance Biopharma (TBPH) as of Q3 2018, up from 86 in Q2 2018.
- Funds reported $1.55B of Theravance Biopharma stock for Q3 2018, up 43% quarter-over-quarter.
- 19 funds opened new Theravance Biopharma positions in Q3 2018 and 10 closed out, a net change of +9 holders.
- The largest Theravance Biopharma buyer in Q3 2018 was Consonance Capital Management, an estimated $19.9M added.
- The largest Theravance Biopharma seller in Q3 2018 was Armistice Capital, an estimated $26.8M sold.
Based on aggregated 13F filings for Q3 2018.